Literature DB >> 7415205

The metabolism of ellagic acid in the rat.

B Doyle, L A Griffiths.   

Abstract

1. Following oral administration of ellagic acid to the rat, 10% of the dose was excreted as 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one in urine and faeces. A second metabolite was detected in urine and faeces but not identified. Both metabolites were of microfloral origin, as their formation was not observed in germ-free rats but was demonstrated when ellagic acid was incubated in vitro with micro-organisms from rat gastro-intestinal tract. 2. Following intraperitoneal, but not oral, administration of ellagic acid, a third metabolite was detected in urine. 3. Unchanged ellagic acid was not detected in faeces or urine of any normal rat examined, but small amounts were detected in the faeces of germ-free animals. 4. Following oral administration of ellagic acid, two conjugates of 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one were detected in bile, whereas intraperitoneal administration resulted in the biliary excretion of three conjugates of an unidentified metabolite.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7415205     DOI: 10.3109/00498258009033752

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  13 in total

1.  Ellagic acid attenuates beryllium sulphate-induced oxidative stress and histopathological alterations of spleen in rats.

Authors:  Yuandi Lei; Tianyi Jiang; Liqin He; Yanping Liu; Zhanbing Sun; Weihua Deng; Lian Huang; Zhaohui Zhang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

Review 2.  Structural features and biological properties of ellagitannins in some plant families of the order Myrtales.

Authors:  Takashi Yoshida; Yoshiaki Amakura; Morio Yoshimura
Journal:  Int J Mol Sci       Date:  2010-01-06       Impact factor: 6.208

3.  The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans.

Authors:  Begoña Cerdá; Juan Carlos Espín; Soledad Parra; Pedro Martínez; Francisco A Tomás-Barberán
Journal:  Eur J Nutr       Date:  2004-01-06       Impact factor: 5.614

4.  Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats.

Authors:  K Sonaje; J L Italia; G Sharma; V Bhardwaj; K Tikoo; M N V Ravi Kumar
Journal:  Pharm Res       Date:  2007-03-22       Impact factor: 4.580

5.  Ellagic acid alleviates adjuvant induced arthritis by modulation of pro- and anti-inflammatory cytokines.

Authors:  Gamal Allam; Emad A Mahdi; Abdullah M Alzahrani; Abdelaziz S Abuelsaad
Journal:  Cent Eur J Immunol       Date:  2017-01-24       Impact factor: 2.085

6.  Inhibitory effect of ellagic acid on N-2-fluorenylacetamide-induced liver carcinogenesis in male ACI/N rats.

Authors:  T Tanaka; H Iwata; K Niwa; Y Mori; H Mori
Journal:  Jpn J Cancer Res       Date:  1988-12

7.  Urolithin A Is a Dietary Microbiota-Derived Human Aryl Hydrocarbon Receptor Antagonist.

Authors:  Gulsum E Muku; Iain A Murray; Juan C Espín; Gary H Perdew
Journal:  Metabolites       Date:  2018-11-29

8.  Anti-inflammatory effects of ellagic acid on acute lung injury induced by acid in mice.

Authors:  Daniely Cornélio Favarin; Maxelle Martins Teixeira; Ednéia Lemos de Andrade; Claudiney de Freitas Alves; Javier Emilio Lazo Chica; Carlos Artério Sorgi; Lúcia Helena Faccioli; Alexandre Paula Rogerio
Journal:  Mediators Inflamm       Date:  2013-02-27       Impact factor: 4.711

9.  Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far.

Authors:  Juan Carlos Espín; Mar Larrosa; María Teresa García-Conesa; Francisco Tomás-Barberán
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-28       Impact factor: 2.629

10.  Antiviral activity and possible mode of action of ellagic acid identified in Lagerstroemia speciosa leaves toward human rhinoviruses.

Authors:  Sang Wook Park; Min Jung Kwon; Ji Young Yoo; Hwa-Jung Choi; Young-Joon Ahn
Journal:  BMC Complement Altern Med       Date:  2014-05-26       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.